
Supplementary material (JCEM / jc.2019-01294)

RESIDUAL ADRENAL FUNCTION IN AUTOIMMUNE ADDISON'S DISEASE – EFFECT OF DUAL THERAPY WITH RITUXIMAB AND DEPOT TETRACOSACTIDE

Catherine Napier¹, Earn H Gan¹, Anna L Mitchell¹, Lorna C Gilligan², D Aled Rees³, Carla Moran⁴, Krishna Chatterjee⁴, Bijay Vaidya⁵, R Andrew James¹, Yaasir Mamoojee⁴, Simon Ashwell⁶, Wiebke Arlt²⁷, Simon HS Pearce⁴



Supplementary figure legend: Panel A shows serum immunoglobulin A, G and M concentrations at baseline, 12- and 48- weeks in the 13 study participants. LLN refers to the lower limit of the reference range. Panel B shows the % of CD19+ lymphocytes out of the total lymphocyte population measured by flow cytometry during the study.

Supplementary Table

Serious Adverse Events*	Number of events	Number of participants (%)
Diarrhoea, vomiting, gastrointestinal illness	3	3 (23%)
Facial laceration (vehicle accident)	1	1 (8%)
*All of the Serious adverse events were classified as SAEs because of hospital attendance. None were classified as treatment-related by the investigators		
Other Adverse Events (excluding inject-site reactions)		
Back pain	84	9 (69%)
Headache		
Fatigue		
Cough		
Poor concentration		
Sinusitis		
Sore throat		
Tonsillitis		
Ear infection		
Chest infection		
Urinary tract infection		
Itchy skin		
Conjunctivitis		
Diarrhoea		
Abdominal pain		
Dizziness		
Dehydration	-	
Cut to hand		
Weight loss		